down arrow

Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

  • Market Cap: Micro Cap
  • Industry: Specialty Chemicals
  • ISIN: CNE100005ZB9
CNY
17.67
-0.39 (-2.16%)

Sep 24

SHE

 View all stocks in this country
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

Why is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. ?

1
With a growth in Net Profit of 1524.43%, the company declared Very Positive results in Mar 26
  • The company has declared positive results for the last 2 consecutive quarters
  • ROCE(HY) Highest at 5.68%
  • RAW MATERIAL COST(Y) Fallen by -197.79% (YoY)
  • NET SALES(Q) Highest at CNY 703.53 MM
2
With ROE of 5.51%, it has a very attractive valuation with a 0.99 Price to Book Value
  • Over the past year, while the stock has generated a return of 67.08%, its profits have risen by 875% ; the PEG ratio of the company is 0
3
Market Beating Performance
  • The stock has generated a return of 67.08% in the last 1 year, much higher than market (China Shanghai Composite) returns of 16.83%
stock-recommendationReal-Time Research Report

Verdict Report

How much should you buy?

  1. Overall Portfolio exposure to Hubei Hongyuan Pharmaceutical Technology Co., Ltd. should be less than 10%
  2. Overall Portfolio exposure to Specialty Chemicals should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Specialty Chemicals)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hubei Hongyuan Pharmaceutical Technology Co., Ltd. for you?

High Risk, High Return

Absolute
Risk Adjusted
Volatility
Hubei Hongyuan Pharmaceutical Technology Co., Ltd.
22.96%
1.46
60.76%
China Shanghai Composite
0.9%
1.20
14.07%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
6.91%
EBIT Growth (5y)
-16.28%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.18
Sales to Capital Employed (avg)
0.36
Tax Ratio
17.14%
Dividend Payout Ratio
16.67%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10,679.39%
ROE (avg)
10.19%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
30
Industry P/E
Price to Book Value
1.64
EV to EBIT
26.59
EV to EBITDA
16.70
EV to Capital Employed
1.73
EV to Sales
3.15
PEG Ratio
0.03
Dividend Yield
NA
ROCE (Latest)
6.52%
ROE (Latest)
5.51%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bullish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bullish
Dow Theory
Mildly Bearish
Mildly Bullish
OBV
Mildly Bearish
Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

30What is working for the Company
PRE-TAX PROFIT(Q)

At CNY 37.29 MM has Grown at 1,763.43%

NET PROFIT(Q)

At CNY 12.66 MM has Grown at 207.68%

ROCE(HY)

Highest at 6.29%

NET SALES(Q)

At CNY 638.42 MM has Grown at 42.15%

RAW MATERIAL COST(Y)

Fallen by -8.93% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 2.63 times

-7What is not working for the Company
DEBT-EQUITY RATIO (HY)

Highest at -14.37 %

INTEREST(Q)

At CNY 2.87 MM has Grown at 11.17%

Here's what is working for Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

Pre-Tax Profit
At CNY 37.29 MM has Grown at 1,763.43%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (CNY MM)

Net Profit
At CNY 12.66 MM has Grown at 207.68%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (CNY MM)

Net Sales
At CNY 638.42 MM has Grown at 42.15%
Year on Year (YoY)
MOJO Watch
Near term sales trend is very positive

Net Sales (CNY MM)

Debtors Turnover Ratio
Highest at 2.63 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -8.93% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hubei Hongyuan Pharmaceutical Technology Co., Ltd.

Interest
At CNY 2.87 MM has Grown at 11.17%
period on period (QoQ)
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio
Highest at -14.37 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Footer loading